Recent advances in pharmacokinetics of polymeric excipients used in nanosized anti-cancer drugs.
The efficacy of drug delivery systems using nanoparticles to enhance the pharmacokinetic properties of drugs has been confirmed in both preclinical trials and clinical settings. A nanosized drug system has improved efficacy, reduced side effects and clearance, increased cellular uptake and prolonged time in circulation. This article will focus recent studies of the pharmacokinetic behavior of such systems as poly(ethylene glycol) and polyamidoamine. Their derivatives are also analyzed. Additionally, some diseases with very good responsiveness are aslo reported.